A detailed history of Mario Gabelli (Gamco Investors, Inc. Et Al) transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Gamco Investors, Inc. Et Al holds 110,894 shares of BMY stock, worth $6.41 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares
110,894
Previous 111,439 0.49%
Holding current value
$6.41 Million
Previous $4.63 Million 23.98%
% of portfolio
0.06%
Previous 0.05%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $21,614 - $28,203
-545 Reduced 0.49%
110,894 $5.74 Million
Q2 2024

Aug 13, 2024

SELL
$40.25 - $52.99 $206,321 - $271,626
-5,126 Reduced 4.4%
111,439 $4.63 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $305,824 - $346,745
-6,374 Reduced 5.18%
116,565 $6.32 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $103,102 - $115,284
-1,781 Reduced 1.43%
122,939 $7.14 Million
Q2 2023

Aug 10, 2023

SELL
$63.71 - $70.74 $531,150 - $589,759
-8,337 Reduced 6.27%
124,720 $7.98 Million
Q1 2023

May 12, 2023

SELL
$65.71 - $74.53 $150,278 - $170,450
-2,287 Reduced 1.69%
133,057 $9.22 Million
Q4 2022

Feb 13, 2023

SELL
$68.48 - $81.09 $371,230 - $439,588
-5,421 Reduced 3.85%
135,344 $9.74 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $91 - $54,249
-706 Reduced 0.5%
140,765 $10 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $1.15 Million - $1.26 Million
-15,783 Reduced 10.04%
141,471 $10.9 Million
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $620,394 - $743,908
-10,091 Reduced 6.03%
157,254 $11.5 Million
Q4 2021

Feb 11, 2022

SELL
$53.63 - $62.52 $783,534 - $913,417
-14,610 Reduced 8.03%
167,345 $10.4 Million
Q3 2021

Nov 12, 2021

BUY
$59.17 - $69.31 $372,771 - $436,653
6,300 Added 3.59%
181,955 $10.8 Million
Q2 2021

Aug 13, 2021

SELL
$61.91 - $67.42 $419,068 - $456,365
-6,769 Reduced 3.71%
175,655 $11.7 Million
Q1 2021

May 14, 2021

SELL
$59.34 - $66.74 $415,854 - $467,713
-7,008 Reduced 3.7%
182,424 $11.5 Million
Q4 2020

Feb 05, 2021

SELL
$57.74 - $65.43 $1.05 Million - $1.19 Million
-18,230 Reduced 8.78%
189,432 $11.8 Million
Q3 2020

Nov 06, 2020

SELL
$57.43 - $63.64 $971,428 - $1.08 Million
-16,915 Reduced 7.53%
207,662 $12.5 Million
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $16 Million - $18.7 Million
-292,473 Reduced 56.57%
224,577 $13.2 Million
Q1 2020

May 14, 2020

BUY
$46.4 - $67.43 $2.23 Million - $3.25 Million
48,138 Added 10.27%
517,050 $28.8 Million
Q4 2019

Feb 14, 2020

BUY
$49.21 - $64.19 $6.87 Million - $8.97 Million
139,692 Added 42.43%
468,912 $30.1 Million
Q3 2019

Nov 01, 2019

SELL
$42.77 - $50.71 $2.49 Million - $2.95 Million
-58,218 Reduced 15.03%
329,220 $16.7 Million
Q2 2019

Aug 02, 2019

SELL
$44.62 - $49.34 $4.96 Million - $5.49 Million
-111,242 Reduced 22.31%
387,438 $17.6 Million
Q1 2019

May 02, 2019

SELL
$45.12 - $53.8 $25,853 - $30,827
-573 Reduced 0.11%
498,680 $23.8 Million
Q4 2018

Jan 30, 2019

SELL
$48.76 - $63.23 $1.99 Million - $2.58 Million
-40,850 Reduced 7.56%
499,253 $26 Million
Q3 2018

Nov 02, 2018

SELL
$55.19 - $62.25 $910,635 - $1.03 Million
-16,500 Reduced 2.96%
540,103 $33.5 Million
Q2 2018

Aug 10, 2018

BUY
$50.53 - $62.98 $4.57 Million - $5.69 Million
90,424 Added 19.4%
556,603 $30.8 Million
Q1 2018

May 09, 2018

BUY
$59.92 - $68.98 $3.45 Million - $3.97 Million
57,577 Added 14.09%
466,179 $29.5 Million
Q4 2017

Feb 02, 2018

SELL
$59.94 - $65.35 $3.55 Million - $3.87 Million
-59,265 Reduced 12.67%
408,602 $25 Million
Q3 2017

Nov 01, 2017

BUY
$55.23 - $63.74 $25.8 Million - $29.8 Million
467,867
467,867 $29.8 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track Mario Gabelli's Portfolio

Track Mario Gabelli Portfolio

Follow Mario Gabelli (Gamco Investors, Inc. Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.